Editas Medicine, Inc. (NASDAQ:EDIT) Receives $15.00 Consensus PT from Analysts

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target […]

Leave a Reply

Your email address will not be published.

Previous post Head to Head Analysis: Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk (NYSE:TLK) versus Singapore Telecommunications (OTCMKTS:SGAPY)
Next post McKesson Co. (NYSE:MCK) Receives $522.21 Average Price Target from Analysts